- Home
- GL vs EXEL Comparison
GL vs EXEL Comparison
Compare GL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GL
- EXEL
- Stock Information
- Founded
- GL 1900
- EXEL 1994
- Country
- GL United States
- EXEL United States
- Employees
- GL N/A
- EXEL N/A
- Industry
- GL Life Insurance
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GL Finance
- EXEL Health Care
- Exchange
- GL Nasdaq
- EXEL Nasdaq
- Market Cap
- GL 11.0B
- EXEL 10.4B
- IPO Year
- GL N/A
- EXEL 2000
- Fundamental
- Price
- GL $132.21
- EXEL $40.69
- Analyst Decision
- GL Buy
- EXEL Buy
- Analyst Count
- GL 10
- EXEL 24
- Target Price
- GL $150.90
- EXEL $44.73
- AVG Volume (30 Days)
- GL 610.7K
- EXEL 3.2M
- Earning Date
- GL 10-22-2025
- EXEL 11-04-2025
- Dividend Yield
- GL 0.82%
- EXEL N/A
- EPS Growth
- GL 16.72
- EXEL 53.55
- EPS
- GL 13.77
- EXEL 2.38
- Revenue
- GL $5,940,974,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- GL $7.51
- EXEL $9.14
- Revenue Next Year
- GL $5.15
- EXEL $12.51
- P/E Ratio
- GL $9.60
- EXEL $17.17
- Revenue Growth
- GL 3.73
- EXEL 9.93
- 52 Week Low
- GL $100.27
- EXEL $31.90
- 52 Week High
- GL $147.83
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- GL 42.01
- EXEL 58.21
- Support Level
- GL $127.85
- EXEL $36.00
- Resistance Level
- GL $134.62
- EXEL $41.55
- Average True Range (ATR)
- GL 2.42
- EXEL 1.39
- MACD
- GL -0.02
- EXEL 0.27
- Stochastic Oscillator
- GL 44.37
- EXEL 87.63
About GL Globe Life Inc.
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.